Patients with hepatitis C who suffer from advanced stages of liver disease have renewed hope, thanks to findings by researchers who have discovered that a new drug significantly reduces their risk of death and need for transplantation.
The research team, led by clinical researchers at Intermountain Healthcare's Intermountain Medical Center in Salt Lake City, studied nearly 1,900 hep C patients and found that the number of patients needing transplants was reduced by 40 percent after they were given a regimen of the drug, sofosbuvir.
Results of the study will be presented at the 2017 International Joint Congress of ILTS, ELITA & LICAGE in Prague, Czech Republic, on Friday, May 26, 2017.
About 3.3 million people in the United States have chronic hepatitis C infection, which causes inflammation of the liver and eventually leads to serious liver problems like cirrhosis, which is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism.
Researchers studied longitudinal data to learn the impact sofosbuvir had in treating patients with advanced stages of cirrhosis. They compared the outcomes of 1,857 patients prior to the United States Food and Drug Administration's approval of sofosbuvir in Dec. 2013 with 623 similar patients who were treated with sofosbuvir after approval of the drug.
"Prior to FDA approval of sofosbuvir, patients with the most advanced stages of cirrhosis either died from their disease or ended up receiving a transplant," said Michael Charlton, MD, lead researcher from Intermountain Healthcare's Intermountain Medical Center Transplant Program, and current president of the International Liver Transplantation Society.
"We found that by treating those patients, who were on the verge of needing a transplant, with sofosbuvir-based therapies, we greatly reduced the liver transplant and mortality rates." Only three percent of patients on sofosbuvir ended up needing a transplant, compared to ovder 40% of untreated patients.
Data used in the study included an integrated database of four separate, prospective, multicenter, multinational randomized controlled clinical trials of sofosbuvir-based therapies in patients with advanced stages of cirrhosis, and compared them with patients who were on the United Network for Organ Sharing (UNOS) waitlist for a liver transplant between 2008-2013.
"We found the sicker a patient was, the more benefit they experienced by using sofosbuvir," said Dr. Charlton. "However, many people around the world who might benefit most from this therapy don't have access to it because the regulatory authorities haven't felt it safe for use in patients with advanced stages of liver disease due to hepatitis C. Our research shows the benefits of this drug include significantly improving the health of even the sickest patients, allowing them to return to their normal life sooner."
Study authors conclude the study by recommending that treatment of the hepatitis C virus using sofosbuvir should be considered in all patients with cirrhosis, even those in advanced stages of the liver disease.
Members of the Intermountain Medical Center Liver Transplantation Program involved in the study include Li Dong; Michael Leise; Richard Gilroy, MD; Jake Krong; Anu Osinusi; Michael P. Curry; Michael Manns; Nezam Afdhal; Diana M. Brainard; and Michael Charlton, MD.
Jess C. Gomez | EurekAlert!
Institutions of higher education spent more than Euro 48 billion in 2014
19.05.2016 | Statistisches Bundesamt
Microtechnology industry keen to invest and innovate
07.04.2016 | IVAM Fachverband für Mikrotechnik
Japanese researchers show the phase separation of two substances depends on the topology of the pore
Researchers at University of Tokyo Institute of Industrial Science (IIS) report a new physical model that shows how the topology of a porous material...
A novel approach to studying the viscosity of water has revealed new insights about the behavior of water molecules and may open pathways for liquid-based electronics.
A team of researchers led by the Department of Energy's Oak Ridge National Laboratory used a high-resolution inelastic X-ray scattering technique to measure...
It is by far the most abundant river in the world. One fifth of the Earth’s entire freshwater supply flows from its mouth into the Atlantic pushing the ocean’s salt water several hundred kilometers out to sea. In April, Andrea Koschinsky, Professor of Geochemistry at Jacobs University, will travel to the estuary of the Amazon – as head of a recently approved, interdisciplinary research project on board the research ship, Meteor.
The Amazon River is almost 7,000 km long and is not only tremendously abundant but it also transports large quantities of trace metals such as iron and copper...
Physicists at the University of Basel have succeeded in cooling a nanoelectronic chip to a temperature lower than 3 millikelvin. The scientists from the Department of Physics and the Swiss Nanoscience Institute set this record in collaboration with colleagues from Germany and Finland. They used magnetic cooling to cool the electrical connections as well as the chip itself. The results were published in the journal Applied Physics Letters.
Even scientists like to compete for records, which is why numerous working groups worldwide are using high-tech refrigerators to reach temperatures as close to...
When scientists recorded a rippling in space-time, followed within two seconds by an associated burst of light observed by dozens of telescopes around the...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
29.12.2017 | Materials Sciences
29.12.2017 | Health and Medicine
29.12.2017 | Life Sciences